Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation
Apichat Kaewdech(Prince of Songkla University), Teerha Piratvisuth(Prince of Songkla University), Teepawit Witeerungrot(Songklanagarind Hospital), Yasuhito Tanaka(Nagoya City University), Sawangpong Jandee(Prince of Songkla University), Pimsiri Sripongpun(Prince of Songkla University), Pisit Tangkijvanich(Chulalongkorn University)
Cited by 46
Related Papers
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
|The Journal of Clinical Endocrinology & Metabolism|2022|306
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
|Clinical Infectious Diseases|2015|149
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
|Clinical Gastroenterology and Hepatology|2023|123
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
|Journal of Hepatology|2022|121